Clinical bottom line
Gastrointestinal complications following organ transplantation remain a significant source of morbidity and mortality, impacting patient quality of life and graft survival. Advances in endoscopic techniques and multidisciplinary management have improved the diagnosis and treatment of common post-transplant GI issues such as biliary strictures, infections, and post-transplant lymphoproliferative disorder (PTLD). However, the complexity of immunosuppression and variable presentations necessitate individualized care and ongoing surveillance. Emerging evidence supports early endoscopic intervention for biliary complications and tailored approaches for gastrointestinal infections and inflammatory conditions after hematopoietic and solid organ transplantation.
What the evidence shows
Post-transplant gastrointestinal complications vary by transplant type but commonly include biliary strictures, infections, pancreatitis, and PTLD. In liver transplantation, biliary complications remain prevalent, with endoscopic management proving effective and durable. A landmark study by Zahr et al. (2011) demonstrated that endoscopic retrograde cholangiopancreatography (ERCP) with stenting is the mainstay for managing biliary strictures, achieving long-term efficacy and reducing the need for surgical revision. This is supported by earlier transplantation data confirming the safety and success of endoscopic approaches (Zahr et al., 2011; &NA; et al., 2006).
Kidney transplant recipients face gastrointestinal complications including pancreatitis and ureteral strictures that may mimic or complicate GI symptoms. Karaoğullarından et al. (2026) highlighted that pancreatitis post-kidney transplant requires prompt recognition and management, with imaging and endoscopic evaluation playing key roles. Additionally, Shaked et al. (2022) emphasized the importance of endoscopic and surgical management of ureteral strictures to preserve graft function, underscoring the need for multidisciplinary care.
Hematopoietic cell transplantation (HCT) recipients frequently develop GI complications such as mucositis, graft-versus-host disease (GVHD), and infections. Bagi Preet et al. (2013) reviewed that early diagnosis and management of GI GVHD and infectious complications are critical, with endoscopy aiding in diagnosis and guiding immunosuppressive therapy adjustments. The heterogeneity of presentations requires careful clinical correlation and often repeated evaluations.
Post-transplant lymphoproliferative disorder (PTLD), a potentially life-threatening complication predominantly seen after liver transplantation, involves the GI tract in many cases. Nakanishi et al. (2012) reported on the incidence and clinical course of PTLD in living-donor liver transplant recipients, noting that early detection and reduction of immunosuppression are key to improving outcomes. Endoscopic biopsy remains essential for diagnosis.
Emerging data also suggest that post-transplant patients may experience long-term GI sequelae including chronic inflammation and altered motility, warranting ongoing surveillance and symptomatic management (Elhence et al., 2022).
Caveats and uncertainty
Most evidence derives from single-center experiences or retrospective cohorts, limiting generalizability. Variability in immunosuppressive regimens, transplant types, and patient comorbidities complicates direct comparisons. The optimal timing and frequency of endoscopic surveillance post-transplant remain undefined. Additionally, the balance between immunosuppression to prevent rejection and the risk of infections or PTLD requires nuanced clinical judgment without robust prospective trial data.
Some interventions, such as endoscopic management of biliary strictures, rely on operator expertise and may not be universally available. The evolving landscape of immunosuppressive agents and antiviral therapies may alter complication profiles, necessitating updated research.
How this may change practice
Clinicians managing transplant recipients should maintain a high index of suspicion for GI complications and integrate early endoscopic evaluation into diagnostic algorithms, especially for biliary and infectious complications. Multidisciplinary collaboration involving transplant surgeons, gastroenterologists, and infectious disease specialists is essential for optimizing outcomes.
Routine surveillance protocols may benefit from refinement to balance early detection with procedural risks. Personalized immunosuppression adjustments guided by endoscopic and histologic findings can improve management of PTLD and GVHD. Awareness of emerging long-term GI complications post-transplant should prompt longitudinal follow-up and symptom-directed therapies.
Overall, advances in endoscopic techniques and a better understanding of post-transplant GI pathology support more proactive and tailored management strategies to reduce morbidity and preserve graft function.